cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Paratek Pharmaceuticals Inc
8 own
31 watching
Current Price
$2.23
$-0.04
(-1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
123.63M
52-Week High
52-Week High
4.25
52-Week Low
52-Week Low
1.6
Average Volume
Average Volume
0.2M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization123.63M
icon52-Week High4.25
icon52-Week Low1.6
iconAverage Volume0.2M
iconDividend Yield--
iconP/E Ratio--
What does the Paratek Pharmaceuticals Inc do?
Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.
Read More
How much money does Paratek Pharmaceuticals Inc make?
News & Events about Paratek Pharmaceuticals Inc.
Globe Newswire
1month ago
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals...
Globe Newswire
1month ago
BOSTON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) today announced that the Companys independent directors of the Board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the ...
Globe Newswire
1month ago
100% Survival Rate in Anthrax-infected Rabbits Treated with OmadacyclineTotal Revenue Recognition to Paratek of $38.1 Million BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced positive top line data from a pilot rabbit efficacy study evaluating ...
Globe Newswire
3 months ago
BOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announces the commercial availability of U.S.-produced NUZYRA (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in the United ...
Globe Newswire
4 months ago
Oct. 3 Webinar Features Presentations by Scientific Leaders in NTM and Parateks Management TeamBOSTON, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving ...
Frequently Asked Questions
Frequently Asked Questions
What is Paratek Pharmaceuticals Inc share price today?
plus_minus_icon
Can Indians buy Paratek Pharmaceuticals Inc shares?
plus_minus_icon
How can I buy Paratek Pharmaceuticals Inc shares from India?
plus_minus_icon
Can Fractional shares of Paratek Pharmaceuticals Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Paratek Pharmaceuticals Inc stocks?
plus_minus_icon
What is today’s traded volume of Paratek Pharmaceuticals Inc?
plus_minus_icon
What is today’s market capitalisation of Paratek Pharmaceuticals Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Paratek Pharmaceuticals Inc?
plus_minus_icon
What percentage is Paratek Pharmaceuticals Inc down from its 52-Week High?
plus_minus_icon
What percentage is Paratek Pharmaceuticals Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$2.23
$-0.04
(-1.76%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00